A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Study Details
Study Description
Brief Summary
This study involves a two-part design. Part 1 is designed to evaluate the safety and tolerability of the 4 drug (HLX10+HLX04+carboplatin+pemetrexed). Part 2 is a randomized, open-label study, which will evaluate the safety and efficacy of HLX10 in combination with carboplatin+pemetrexed with or without HLX04(biosimilar of avastin) compared with treatment with carboplatin+pemetrexed in 1st line Stage IIIB/IIIC or IV non-squamous NSCLC. Participants will be randomized in a 1:1:1 ratio to Arm A (HLX10+HLX04+Carboplatin+Pemetrexed), Arm B (HLX10+HLX04 placebo+Carboplatin+Pemetrexed), or Arm C (HLX10 placebo + HLX04 placebo+Carboplatin+Pemetrexed).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Part 1-Cohort 1 (HLX10+HLX04+Carboplatin+Pemetrexed) Participants will receive IV infusion of HLX10 and HLX04 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and HLX04 and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase. |
Drug: HLX10, an engineered anti-PD-1 antibody
HLX10 will be administered as IV infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until loss of clinical benefit or up to 2 year.
Drug: HLX04, a bevacizumab biosimilar
HLX04 will be administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
Drug: Carboplatin
Carboplatin will be administered at area under the concentration-time curve (AUC) 5 on Day 1 of each 21-day cycle for 4 cycles, or until loss of clinical benefit whichever occurs first.
Drug: Pemetrexed
Pemetrexed will be administered as IV infusion at a dose of 500 milligrams per square meter (mg/m2) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
|
| Experimental: Part 2-Arm A (HLX10+HLX04+Carboplatin+Pemetrexed) Participants will receive IV infusion of HLX10 and HLX04 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and HLX04 and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase. |
Drug: HLX10, an engineered anti-PD-1 antibody
HLX10 will be administered as IV infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until loss of clinical benefit or up to 2 year.
Drug: HLX04, a bevacizumab biosimilar
HLX04 will be administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
Drug: Carboplatin
Carboplatin will be administered at area under the concentration-time curve (AUC) 5 on Day 1 of each 21-day cycle for 4 cycles, or until loss of clinical benefit whichever occurs first.
Drug: Pemetrexed
Pemetrexed will be administered as IV infusion at a dose of 500 milligrams per square meter (mg/m2) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
|
| Experimental: Part 2-Arm B (HLX10+HLX04 placebo+Carboplatin+Pemetrexed) Participants will receive IV infusion of HLX10 and HLX04 placebo on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase. |
Drug: HLX10, an engineered anti-PD-1 antibody
HLX10 will be administered as IV infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until loss of clinical benefit or up to 2 year.
Drug: Carboplatin
Carboplatin will be administered at area under the concentration-time curve (AUC) 5 on Day 1 of each 21-day cycle for 4 cycles, or until loss of clinical benefit whichever occurs first.
Drug: Pemetrexed
Pemetrexed will be administered as IV infusion at a dose of 500 milligrams per square meter (mg/m2) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
|
| Active Comparator: Part 2-Arm C (HLX10 placebo+HLX04 placebo+Carboplatin+Pemetrexed) Participants will receive IV infusion of HLX10 placebo and HLX04 placebo on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase. |
Drug: Carboplatin
Carboplatin will be administered at area under the concentration-time curve (AUC) 5 on Day 1 of each 21-day cycle for 4 cycles, or until loss of clinical benefit whichever occurs first.
Drug: Pemetrexed
Pemetrexed will be administered as IV infusion at a dose of 500 milligrams per square meter (mg/m2) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
|
Outcome Measures
Primary Outcome Measures
- Part 1 Safety and tolerability of study treatment [baseline to 21 days]
- Part 2-Progression Free Survival (PFS) as Determined by the IRRC using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) [Baseline until disease progression or death, whichever occurs first (up to approximately 24months)]
Secondary Outcome Measures
- Part 2-Overall survival (OS), as a major secondary endpoint [Baseline until death (up to approximately 36 months)]
- Part 1 and 2-Incidence rates of AEs and SAEs [Baseline up to approximately 36months]
- Part 1-Overall survival (OS) [Baseline up to approximately 36months]
- Part 1 and Part 2-PFS (assessed by the investigator according to RECIST v1.1) in Part 1 and 2; PFS (assessed by IRRC according to RECIST v1.1) in Part 1 [Baseline until disease progression or death, whichever occurs first (up to approximately 36months)]
- Part 1 and 2-Objective response rate (ORR, assessed by IRRC and investigator according to RECIST v1.1 criteria) [Baseline up to approximately 36 months]
- Part 1 and 2-Duration of response (DOR, assessed by IRRC and investigator according to RECIST v1.1 criteria) [Baseline up to approximately 36 months]
- Part 2-PFS2 (assessed by IRRC) [Baseline up to approximately 36months]
- Part 1 and 2-Pharmacokinetics (PK): serum HLX10 concentration [Baseline up to approximately 36 months]
- Part 1 and 2-Immunogenicity evaluation: positive anti-drug antibody (ADA) rate [Baseline up to approximately 36 months]
- Part 1 and 2-PD-L1 expression level [Baseline]
- Part 1 and 2-Microsatellite instability(MSI) [Baseline]
- Part 1 and 2-Tumor mutation burden(TMB) [Baseline]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically or cytologically confirmed, Stage IIIB/IIIC or IV non-squamous NSCLC
-
Participants with no EGFR, ALK and ROS1 mutation.
-
Participants with no prior treatment for Stage IIIB/IIIC or IV non-squamous NSCLC
-
Measurable disease as defined by RECIST v1.1
-
Eastern Cooperative Oncology Group performance status 0 or 1
-
Adequate hematologic and end organ function
Exclusion Criteria:
-
Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
-
Active central nervous system metastases
-
Prior treatment with cluster of differentiation immune checkpoint blockade therapies or Bevacizumab
-
Has received a surgical operation within 4 weeks from the initial drug administration
-
Active or suspected autoimmune diseases. Subjects in a stable state with no need for systemic immunosuppressant therapy are allowed to enroll.
-
Currently having or have had interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis and severe impaired pulmonary function that may interfere with the detection and management of suspected drug-related pulmonary toxicity
-
Any active infection requiring systemic anti-infective therapy within 14 days prior to study drug administration
-
Uncontrollable active infection(s)
-
History of immunodeficiency, including HIV antibody positive
-
active hepatitis B; or hepatitis C virus infections
-
Has bleeding tendency
-
History of severe cardiovascular diseases
-
Known gastrointestinal diseases as follows, Gastrointestinal perforation, abdominal fistula or abdominal abscess within 6 months before signing the informed consent; History of poorly controlled or recurrent inflammatory bowel disease; Active peptic ulcers, or > moderate esophageal varices
-
Pregnant or breastfeeding female
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Cancer Hospital Chinese Academy of Medical Sciences (CAMS) | Beijing | Beijing | China | 100000 |
Sponsors and Collaborators
- Shanghai Henlius Biotech
Investigators
- Principal Investigator: Yankai Shi, professor, Cancer Hospital Chinese Academy of Medical Sciences (CAMS)
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HLX10-002-NSCLC301